AccurKardia delivers its ECG interpretation software within the Lucem Health Reveal family of clinical AI solutions

0
25

Share on LinkedIn

New Partnership Paves the Way for Early Diagnosis and Intervention to Improve Cardiovascular Outcomes & Quality of Life for Patients

NEW YORK, NOVEMBER 9, 2023 AccurKardia, an ECG-led diagnostics software company, today announced a multi-year agreement with Lucem Health, a leading provider of clinical AI solutions. The partnership paves the way for AccurKardia to integrate its FDA-Cleared ECG Interpretation Software Platform, AcurrECGTM Analysis System (“AccurECG”), into Lucem Health Reveal, a family of solutions that identify patients who may be at higher risk of severe or chronic diseases.

AccurKardia’s AccurECG is a cloud-based, device-agnostic, fully automated ECG interpretation software platform that can detect up to 13 arrhythmias. This technology assists cardiac monitoring companies in analyzing ECGs recorded from a wide array of inputs from wet electrode devices.

“Our software helps clinicians review ECGs more efficiently and enables prompt treatment of patients, with key cardiovascular insights delivered in minutes. This partnership with Lucem Health allows us to bring the power of our technology to Lucem Health’s clinical AI solution,” said Juan C. Jiménez, CEO of AccurKardia. “This is an important step in our mission to improve patients’ outcomes and save lives at scale.”

“Lucem Health’s Reveal solutions provide a unique way to identify patient health risks hiding in plain sight. Our partnership with AccurKardia enables us to extend Reveal’s benefits to cardiovascular diseases,” said Jeremy E. Pierotti, General Manager of Solutions at Lucem Health. “We’re committed to providing clinicians with the most advanced tools for early diagnosis and intervention of chronic diseases. Later this year, we’ll announce our first product incorporating AccurKardia’s FDA-cleared technology.”

About AccurKardia

AccurKardia is an ECG-led diagnostics software company unlocking the value of the ECG signal for broad diagnostics coverage and disease management ultimately improving clinical outcomes and saving lives at a planetary scale. AccurKardia’s first FDA-cleared product, AccurECG (Class II SaMD), is a cloud-based and device-agnostic software for fully automated ECG interpretation and detection for up to 13 arrhythmias. The technology assists cardiac monitoring companies in the analysis of ECGs recorded from holters, event recorders, and cardiac telemetry devices. The Company completed Cohort 3 of Mayo Clinic Platform_Accelerate in July 2023. For more information about AccurKardia, please visit: https://www.accurkardia.com/.

About Lucem Health

Lucem Health helps healthcare providers accelerate disease detection and treatment using practical, responsible AI, so they can improve patients’ lives and increase the clinical and financial yield from today’s scarce care delivery resources. We envision a world in which clinicians detect problems before they become life-threatening and patients get world-class care, everywhere. Learn more at www.lucemhealth.com.

News Editor
CustomerThink offers a free news posting service for press releases relevant to our community. To submit your press release to our news editor, send an email to [email protected] with the press release headline and main content in the email subject line and body, respectively. That's it! Approved press releases will appear in our news category within one business day of submission.

ADD YOUR COMMENT

Please use comments to add value to the discussion. We will not publish brief comments like "good post" or comments that mainly promote links. All comments are reviewed by moderator before publication.

Please enter your comment!
Please enter your name here